NeuroSigma has announced that the Mexican Institute of Industrial Property has issued a Notice of Allowance for Mexican Patent Application No. MX/a/2012/004051. The patent application is co-owned by NeuroSigma and the Regents of the University of California as a result of research conducted by physicians and scientists at NeuroSigma and the University of California, Los Angeles (UCLA). NeuroSigma is the exclusive licensee of the Regents’ rights to the patent application.
The patent application is related to the use of trigeminal nerve stimulation with minimally invasive, subcutaneously implanted electrodes and pulse generator for the treatment of a wide variety of medical disorders including neurological and neuropsychiatric disorders such as epilepsy, depression, post-traumatic stress disorder, attention deficient hyperactivity disorder, and traumatic brain injury.
“NeuroSigma has previously received several US patents related to our external and subcutaneous trigeminal nerve stimulation systems. We are very pleased to be receiving our first non-US patent related to our minimally invasive, fully implantable subcutaneous trigeminal nerve stimulation system, which is currently under development. It is an important step in obtaining patent coverage in markets outside of the USA in support of our global commercialisation strategy,” says David Hayes, chief administrative officer and general counsel of NeuroSigma.